Unfortunately, long term administration of anti-VEGF treatments raises therapy resistance (21, 22) and major reductions in tumor blood vessels are not achieved, likely due to the activation of alternative neovascularization events in tumors (23, 24). The gene discussed is VEGFA; the disease is neoplasm.